Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.79 |
| ▸ | JAK2 | O60674 | 17/20 | 0.71 |
| ▸ | JAK3 | P52333 | 17/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313148 | 0.92 | AURKA (0.79) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL3147202 | 0.89 | JAK2 (0.70) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13313163 | 0.88 | AURKA (1.00) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13666776 | 0.88 | AURKA (1.00) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL3147902 | 0.88 | AURKA (1.00) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL3557452 | 0.82 | AURKA (0.71) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13313149 | 0.82 | AURKA (0.71) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13313230 | 0.82 | AURKA (0.74) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13313225 | 0.82 | AURKA (0.74) | AURKAAURKBJAK2JAK3CHEK1 | |
| SCHEMBL13313099 | 0.81 | AURKA (0.80) | AURKAAURKBJAK2JAK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689739-B1 | AZOLE-BASED KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-03-30 | — | — | EP | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | PRKACA, MAP3K6, PRKDC | AURKA 486/4885AURKB 837/4885JAK2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.